Covishield vaccine experience in a health care setting

Hari Kishan Boorugu, Krushna Chandra Misra, B. Saroj Kumar Prusty


Background: SARS-CoV-2 pandemic has affected the whole world and India is one among the most affected countries. Vaccination is the most important tool to halt this pandemic and vaccine hesitancy unfortunately derails vaccination drive. Vaccine hesitancy among people is mainly due to concerns about vaccine safety! This study was done to assess adverse effects of Covishield vaccine among health care workers in a single health care organization.

Methods: All the vaccine recipients were requested to answer a questionnaire with demographic details and various side effects following both the doses of Covishield vaccination.

Results: About 665 employees responded to the questionnaire and the most common adverse reaction following Covishield vaccine was injection site pain, which was reported by 63% of vaccinees after first dose of vaccine.

Conclusions: Covishield vaccine is relatively safe and incidence of major adverse events are rare following vaccination.


Covishield, Safety, Health care workers, Adverse effect

Full Text:



Fridman A, Gershon R, Gneezy A. COVID-19 and vaccine hesitancy: A longitudinal study. PLoS ONE. 2021;16(4):e0250123.

WHO. Fact sheet: Coronavirus disease (COVID-19) Dashboard, 2020. https://COVID19. Accessed on 11 June 2021.

Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;S1473-3099(21)00070-0.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.

Karim SSA. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet. 2021;397(10281):1263-4.

Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351-62.

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-98.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.

Kataria, Sharma S, Deswal P, Vikas et al. A Real-World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report. medRxiv. 2021;04.14.21255452.

Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.

Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021.

Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet. 2021;397(10285):e11.

European Medicines Agency (EMA). EMA assessment report EMA/158424/2021. https:// ort/covid-19-vaccine-janssen-epar-public-asses sment-report_en.pdf. Accessed on 13th May, 2021.

Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372:n699.

European Medicines Agency (EMA). COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks - Update. cine-astrazeneca-prac-investigating-cases-thromb oembolic-events-vaccines-benefits. Accessed on 13th May, 2021.